4142:TPE
Adimmune Corp
16,80 TWD
arrow_upward
+0,60%(+0,100) 1J
13 nov., 13:30:11 UTC+8 · TWD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour 4142...
Ouverture
16,85 TWD
Élevé
17,15 TWD
Faible
16,75 TWD
Cap. boursière
7,22 Md
Vol. moyen
1,13 M
Volume
724,64 k
+ haut sur 1 an
22,50 TWD
+ bas sur 1 an
15,65 TWD
BPA
-0,34 TWD
Actions en circulation
235,29 M
Nombre d'employés
564
Ouverture
16,85 TWD
Élevé
17,15 TWD
Faible
16,75 TWD
Cap. boursière
7,22 Md
Vol. moyen
1,13 M
Volume
724,64 k
+ haut sur 1 an
22,50 TWD
+ bas sur 1 an
15,65 TWD
BPA
-0,34 TWD
Actions en circulation
235,29 M
Nombre d'employés
564
Articles
Sources : Web et partenaires du secteur de l'information
www.tmgm.com
·
il y a 21 heures
Les contrats à terme sur le Dow Jones reculent sur fond de craintes d’une hausse des taux de la Fed et de remaniement de la direction de Nvidia ; les chiffres des prix à la production sont attendus
Vietnam.vn
·
il y a 23 heures
Le S&P 500 et le Nasdaq ont mis fin à leurs séries de quatre semaines de baisse.
TradingKey
·
il y a 4 heures
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
TradingView
·
il y a 9 heures
SpaceX's S&P 500 bid gets new life as Elon Musk pitches Tesla merger
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
À propos de Adimmune Corp